Part II. Development of novel colchicine-derived immunosuppressants with improved pharmacokinetic properties.

We have developed a new series of immunosuppressant with improved pharmacokinetic properties as the second-generation of colchicine analogs, which were designed based on the privileged structure derived from our previous work. In particular, we identified an analog (14), which exhibited a potent in vitro activity (IC(50): 5 nM) in MLR and excellent in vivo efficacy in the Zymosan A-induced arthritis model, in the Carrageenan-induced edema model and in the local lymph node assay (LLNA). Analog 14 also revealed a good oral bioavailability (F: 67.3%) in BALB/c mice.

[1]  A. Brossi,et al.  Facile conversion of natural colchicine into (.+-.)-congeners and (+)-enantiomers including 2-demethyl analogs , 1986 .

[2]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[3]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[4]  A. Brossi,et al.  Antitumor agents--CLXXV. Anti-tubulin action of (+)-thiocolchicine prepared by partial synthesis. , 1997, Bioorganic & medicinal chemistry.

[5]  A. Brossi,et al.  A novel synthesis of colchicide and analogues from thiocolchicine and congeners: reevaluation of colchicide as a potential antitumor agent. , 1987, Journal of medicinal chemistry.

[6]  D. Wilkes,et al.  Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. , 2005, Proceedings of the American Thoracic Society.

[7]  H. Walborsky,et al.  Cyclopropanes. XXV. Cyclopropyl anion , 1970 .

[8]  Jodi M. Smith,et al.  Current immunosuppressive agents: efficacy, side effects, and utilization. , 2003, Pediatric clinics of North America.

[9]  B. Belleau,et al.  N-carboxylic acid esters of 1,2- and 1,4-dihydroquinolines. A new class of irreversible inactivators of the catecholamine alpha receptors and potent central nervous system depressants. , 1968, Journal of the American Chemical Society.

[10]  J. Klein,et al.  SEROLOGICALLY DEFINED AND LYMPHOCYTE-DEFINED COMPONENTS OF THE MAJOR HISTOCOMPATIBILITY COMPLEX IN THE MOUSE , 1972, The Journal of experimental medicine.

[11]  Hatsuo Aoki,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987 .

[12]  N. Mahmud,et al.  Antibody immunosuppressive therapy in solid-organ transplant , 2010 .

[13]  D. Dunn,et al.  CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERS , 1979, The Lancet.

[14]  H. Lillehoj.  Effects of immunosuppression on avian coccidiosis: cyclosporin A but not hormonal bursectomy abrogates host protective immunity , 1987, Infection and immunity.

[15]  J. H. Harrison,et al.  Kidney Transplantation Between Seven Pairs of Identical Twins , 1958, Annals of surgery.

[16]  D. Speicher,et al.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A. , 1984, Science.

[17]  R. Carlson,et al.  Effect of selected antiinflammatory agents and other drugs on zymosan, arachidonic acid, PAF and carrageenan induced paw edema in the mouse , 1987, Agents and Actions.

[18]  Ian Kimber,et al.  The local lymph node assay: past, present and future , 2002, Contact dermatitis.

[19]  Jong-Wha Jung,et al.  Design, synthesis and identification of novel colchicine-derived immunosuppressant. , 2009, Bioorganic & Medicinal Chemistry Letters.

[20]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[21]  H. Fung.  Pharmacokinetics and pharmacodynamics of organic nitrates. , 1987, The American journal of cardiology.

[22]  M. M. Pompeu,et al.  Periarthritis promotes gait disturbance in zymosan-induced arthritis in rats , 1999, Inflammation Research.

[23]  N. Mahmud,et al.  Antibody immunosuppressive therapy in solid organ transplant , 2010, mAbs.

[24]  H. van Loveren,et al.  Use of the local lymph node assay in assessment of immune function. , 2005, Toxicology.

[25]  P. Keown.  Emerging Indications for the Use of Cyclosporin in Organ Transplantation and Autoimmunity , 1990, Drugs.